|
(Health-NewsWire.Net, May 07, 2015 ) Researchmoz presents this most up-to-date research on Hepatitis C Therapeutics in Major Developed Markets to 2019 (http://www.researchmoz.us/hepatitis-c-therapeutics-in-major-developed-markets-to-2019-outstanding-recent-approvals-and-late-stage-pipeline-to-transform-clinical-and-commercial-landscape-report.html). GBI Research, has released the pharma report - "Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape". The current Hepatitis C treatment landscape consists of a combination of pegylated interferon, ribavirin and, in patients infected with genotype 1 hepatitis C, one of two direct-acting antiviral agents (DAAs). Products with these mechanisms of action have performed strongly in the commercial setting, with the market leader Incivek (a DAA) having reached blockbuster sales. However, these products are very poorly tolerated and only moderately efficacious. The approval of the DAA Sovaldi in December 2013 changed this, with a complete viral clearance being achieved in close to 100% of patients and a much improved adverse event profile compared to previous standards of therapy. In patients with genotype 2 and 3 hepatitis C, Sovaldi does not need to be administered with pegylated interferon. A number of products in the late-stage pipeline, which promise to be even more efficacious and safe are anticipated to enter the market over the forecast period, including several interferon-free therapies for genotype 1-infected patients. As a result of this, as well as an overall increase in the treated population, GBI Research believes the global market has the potential to grow to a value of $18.6 billion by 2019, more than tripling the 2012 market value of $5.8 billion.
Scope
A brief introduction to hepatitis C, including the disease's pathogenesis, risk factors and diagnosis, and detailed analyses of disease epidemiology and treatment algorithms.
In-depth analysis of the major antiviral drugs used in the treatment of hepatitis C, including analyses of their safety, efficacy, treatment patterns and strengths/weaknesses. Includes a heat map that compares marketed drugs in terms of safety and efficacy.
A comprehensive review of the pipeline for hepatitis C therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed by phase distribution, molecule type and molecular target.
In-depth clinical trial enrolment, trial duration and program failure rate analyses for each molecule type and mechanism of action. Additionally, clinical trial endpoints and certain selection criteria are analyzed in great depth. This section also includes an additional heat map regarding pipeline products, and a direct cross-analysis against currently marketed products.
Multi-scenario forecast data of the market to 2019, which takes into account the effects of the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets: US, Canada, Japan, Germany, UK, France, Italy and Spain.
Discussion of the drivers and barriers for market growth.
Analysis of licensing and co-development deals occurring in the hepatitis C market.
Reasons to Buy
Understand the different types of hepatitis C therapies and how treatment varies by genotype.
Understand the treatment algorithms and guidelines related to hepatitis C, how they are anticipated to change during the forecast period and where opportunities and unmet needs lie.
Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are most prominent.
Observe trends in clinical trial duration and size as clinical phase and molecule type varies. Use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for hepatitis C therapeutics.
Observe the shift in clinical trial endpoints with each clinical Phase, and use this data to potentially influence any future developmental programs. Additionally, understand the trends in enrolment by patient genotype.
Assess the potential clinical and commercial impact of current late-stage pipeline molecules and the points of opportunity which remain to be capitalized upon.
Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Signs and Symptoms
2.2 Etiology and Risk Factors
2.3 Pathophysiology
2.4 Epidemiology
2.4.1 US and Canada
2.4.2 Europe
2.4.3 Japan
2.4.4 Regional Prevalence of Hepatitis C Genotypes
2.5 Prognosis
2.6 Diagnosis and Screening
2.7 Treatment
2.8 Treatment Algorithms
3 Marketed Products
3.1 Ribavirin
3.2 Pegasys (Peginterferon alfa 2a) and PegIntron (Peginterferon alfa 2b) - Hoffmann La Roche and Merck & Co
3.2.1 Pegasys - Hoffmann La Roche
3.2.2 PegIntron - Merck & Co
3.3 Incivek (telaprevir) - Vertex Pharmaceuticals and Janssen-Cilag
3.4 Victrelis (boceprevir) - Merck & Co
3.5 Olysio (simeprevir) - Johnson and Johnson
3.6 Sovaldi (sofosbuvir) - Gilead Sciences
3.7 Heat Map for Marketed Products
Related & Recently Added Reports by Researchmoz.us to its store.
Ophthalmology Therapeutics in Major Developed Markets (http://www.researchmoz.us/ophthalmology-therapeutics-in-major-developed-markets-to-2019-new-drug-approvals-and-promising-pipeline-to-trigger-shift-in-treatment-paradigm-to-combination-therapies-report.html) GBI Research has released its pharma research, "Ophthalmology Therapeutics in Major Developed Markets to 2019 - New Drug Approvals and Promising Pipeline to Trigger Shift in Treatment Paradigm to Combination Therapies", which provides insights into two therapeutic indications in ophthalmology in Top Eight Markets of the US, the UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an in-depth analysis of the therapeutic indications of ophthalmology, namely glaucoma and Dry Eye Syndrome (DES). The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis for these two ophthalmology indications.
Cystic Fibrosis Therapeutics in Major Developed Markets to 2019 (http://www.researchmoz.us/cystic-fibrosis-therapeutics-in-major-developed-markets-to-2019-cftr-modulators-initiate-drive-towards-personalized-treatment-and-market-growth-report.html) GBI Research has released its pharma report "Cystic Fibrosis Therapeutics in Major Developed Markets to 2019 - CFTR Modulators Initiate Drive Towards Personalized Treatment and Market Growth." The value of the Cystic Fibrosis (CF) market is expected to increase significantly in value over the forecast period across the leading eight developed nations, from $695.6 million in 2012 to almost $4.5 billion in 2019. This equates to a Compound Annual Growth Rate (CAGR) of 30.4%. Novel treatments with disease-modifying mechanisms of action are the primary factor driving the growth of the value of the market. The positive impact of new market entrants will offset the effects of key patent losses during the forecast period.
Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 (http://www.researchmoz.us/systemic-psoriasis-therapeutics-in-major-developed-markets-to-2020-continued-uptake-of-biologics-and-novel-pipeline-drugs-to-drive-growth-description-report.html) GBI Research has released its pharma report "Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growth". The systemic psoriasis market is forecast to grow substantially over the forecast period from $5.0 billion in 2013 to $10.4 billion in 2020, across the eight major markets. This growth will be driven by a rising treatment population and the continued uptake of biologics. Biologics will continue to drive market growth despite leading brands Enbrel (etanercept), Humira (adalimumab) and Remicade (infliximab) losing patent protection in most of the major markets over the forecast period.
Gastrointestinal Therapeutics in Major Developed Markets to 2019 (http://www.researchmoz.us/gastrointestinal-therapeutics-in-major-developed-markets-to-2019-new-drug-approvals-and-promising-pipeline-to-counter-declines-from-patent-expiries-report.html) GBI Research, the leading business intelligence provider, has released its latest research, 'Gastrointestinal Therapeutics (Irritable Bowel Syndrome, Ulcerative Colitis and Crohn's Disease) in Major Developed Markets', which provides insights into three gastrointestinal therapeutic indications in the major developed markets of the US, the UK, France, Germany, Italy, Spain, Japan and Canada. The report provides an in-depth analysis of three gastrointestinal therapeutics markets, namely Irritable Bowel Syndrome (IBS), Ulcerative Colitis (UC) and Crohn's Disease (CD).
Explorer More GBI Research Market Research Reports Publishing Reports at: http://www.researchmoz.us/publisher/gbi-research-2.html
Researchmoz Global Pvt.Ltd
Researchmoz
+1-518-618-1030
sales@researchmoz.us
Source: EmailWire.Com 
|
